Tirzepatide, a drug approved for the treatment of type 2 diabetes, could be on its way to becoming a new drug to treat obesity as well, now that the U.S. Food and Drug Administration (FDA) has granted it a Fast Track designation.
Marketed for type 2 diabetes as Mounjaro, the drug can lead to dramatic weight loss and a significant reduction in A1C, or average blood sugar levels, in people with type 2 diabetes. Mounjaro is now commercially available for that group, says Maggie Pfeiffer, the associate director of Lilly Diabetes Communications (Eli Lilly and Company manufactures the drug). This once-weekly injection was approved by the FDA as a new class of medication for people with type 2 diabetes on May 13, 2022.
Reviews
There are no reviews yet.